EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis

Xinyue Hu, Xiaowei Tang, Limin Li, Lian Luo, Xinsen He, Qin Yan, Xiaolin Zhong

BMC Gastroenterology · 2024

DOI: 10.1186/s12876-024-03480-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Xinyue Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Infliximab, Remission Induction, Gastrointestinal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsInfliximabRemission InductionGastrointestinal AgentsCrohn DiseaseColitis, UlcerativeHumansAntibodies, MonoclonalInflammatory Bowel DiseasesTreatment Outcome

Stichwörter der Autor:innen

CT-P13Crohn’s diseaseInflammatory bowel diseaseInfliximabMeta-analysisMucosal healingUlcerative colitis

Substanzen

Biosimilar PharmaceuticalsCT-P13InfliximabGastrointestinal AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
  • Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. zhongxl519@hotmail.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Sichuan Province

Zitieren

APA

Hu, X., Tang, X., Li, L., Luo, L., He, X., Yan, Q., & Zhong, X. (2024). The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03480-9

Vancouver

Hu X, Tang X, Li L, Luo L, He X, Yan Q, et al. The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03480-9

BibTeX
@article{Hu2024,
  author = {Hu, Xinyue and Tang, Xiaowei and Li, Limin and Luo, Lian and He, Xinsen and Yan, Qin and Zhong, Xiaolin},
  title = {The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis},
  journal = {BMC Gastroenterology},
  year = {2024},
  doi = {10.1186/s12876-024-03480-9}
}
Kostenlos starten →